<DOC>
	<DOCNO>NCT02094443</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacodynamic ( i.e . hepatitis C virus ( HCV ) viral load ) , pharmacokinetic safety profile two treatment group receive different dos DEB025 combination ribavirin ( RBV ) first 12 week treatment chronic hepatitis C genotype ( GT ) -2 GT-3 patient previously fail interferon therapy intolerant unable take interferon .</brief_summary>
	<brief_title>Alisporivir With RBV Chronic Hepatitis C Genotype 2 3 Participants Whom Interferon Not Option</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform 2 . Participants HCV genotype 2 3 infection previously fail interferon therapy intolerant unable take interferon 3 . Males female age â‰¥18 year 4 . Diagnosed Chronic hepatitis C virus infection Exclusion criterion : 1 . Use investigational drug time enrollment , within 30 day 5 halflives medication enrollment 2 . History hypersensitivity study drug drug similar chemical class 3 . Hepatitis B surface antigen ( HBsAg ) positive 4 . Human immunodeficiency virus ( HIV ) positive Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic hepatitis C genotype 2</keyword>
	<keyword>Chronic hepatitis C genotype 3</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
	<keyword>Interferon intolerant</keyword>
</DOC>